Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    Episode 8: Oncology trial design and statistics with Dr. Pavlos Msaouel

    Episode 8: Oncology trial design and statistics with Dr. Pavlos Msaouel

    FromThe View on GU | with Lalani and Wallis

    Start listeningView podcast show

    Episode 8: Oncology trial design and statistics with Dr. Pavlos Msaouel

    FromThe View on GU | with Lalani and Wallis

    ratings:
    Length:
    36 minutes
    Released:
    May 27, 2024
    Format:
    Podcast episode

    Description

    Joined by MD Anderson Cancer Center clinician and scientist Dr. Pavlos Msaouel, Dr. Aly-Khan Lalani and Dr. Christopher Wallis discuss trial design and statistics in oncology. What are the nuances to reading KM curves? How useful are forest plots? Our guest and hosts dive into this and more in Episode 8.
    The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practicing clinicians in the field of genitourinary (GU) cancers.
    Learn more about The View on GU: https://theviewongu.com
    This podcast has been made possible through financial support by AstraZeneca, Bristol Myers Squibb, Merck, and TerSera.
    Released:
    May 27, 2024
    Format:
    Podcast episode

    Titles in the series (11)

    There is currently a lack of organic multi-disciplinary discussion on what is truly impactful to the field of genitourinary (GU) cancers. The View on GU with Lalani and Wallis is a podcast that will integrate key clinical data from major conferences and high impact publications into meaningful take home messages for practicing clinicians. Importantly, Lalani and Wallis will also discuss the impact of governmental approvals and funding considerations on the GU oncology treatment landscape and provide practical considerations on the management of patients on new-to-market therapies.